Double-blind, Placebo Controlled, Randomized, Multicenter Study to Assess the Safety and Clinical Benefit of Rasagiline as an Add on Therapy to Stable Dose of Dopamine Agonists in the Treatment of Early Parkinson's Disease.

Trial Profile

Double-blind, Placebo Controlled, Randomized, Multicenter Study to Assess the Safety and Clinical Benefit of Rasagiline as an Add on Therapy to Stable Dose of Dopamine Agonists in the Treatment of Early Parkinson's Disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 May 2016

At a glance

  • Drugs Rasagiline (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms ANDANTE
  • Sponsors Teva Neuroscience; Teva Pharmaceutical Industries
  • Most Recent Events

    • 20 Jun 2013 Results presented at the 17th International Congress of Parkinson's Disease and Movement Disorders.
    • 18 Jun 2013 Results will be presented at the 17th Annual International Congress of Parkinson's Disease and Movement Disorders, according to a Teva media release.
    • 23 Mar 2013 Results presented at the 65th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top